Cargando…
Intranasal administration of a stapled relaxin‐3 mimetic has anxiolytic‐ and antidepressant‐like activity in rats
BACKGROUND AND PURPOSE: Depression and anxiety are common causes of disability, and innovative tools and potential pharmacological targets are actively sought for prevention and treatment. Therapeutic strategies targeting the relaxin‐3 peptide or its primary endogenous receptor, RXFP3, for the treat...
Autores principales: | Marwari, Subhi, Poulsen, Anders, Shih, Norrapat, Lakshminarayanan, Rajamani, Kini, R. Manjunatha, Johannes, Charles William, Dymock, Brian William, Dawe, Gavin Stewart |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811745/ https://www.ncbi.nlm.nih.gov/pubmed/31220339 http://dx.doi.org/10.1111/bph.14774 |
Ejemplares similares
-
Relaxin’ the brain: a case for targeting the nucleus incertus network and relaxin‐3/RXFP3 system in neuropsychiatric disorders
por: Kumar, Jigna Rajesh, et al.
Publicado: (2016) -
Antidepressants, anxiolytics, and hypnotics in pregnancy and lactation
por: Ram, Daya, et al.
Publicado: (2015) -
Anxiolytic Action of Taurine via Intranasal Administration in Mice
por: Jung, Jung Hwa, et al.
Publicado: (2019) -
Nanosystems, Drug Molecule Functionalization and Intranasal Delivery: An Update on the Most Promising Strategies for Increasing the Therapeutic Efficacy of Antidepressant and Anxiolytic Drugs
por: Antunes, Jéssica L., et al.
Publicado: (2023) -
The Role of Pharmacogenetics in Personalizing the Antidepressant and Anxiolytic Therapy
por: Radosavljevic, Milica, et al.
Publicado: (2023)